Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.78 |
| ▸ | HTR6 | P50406 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 4/20 | 0.73 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | DRD1 | P21728 | 2/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.62 |
| ▸ | DRD5 | P21918 | 2/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465788 | 0.94 | HTR2A (0.88) | HTR2AHTR6HTR1ABCHECYP2D6 | |
| SCHEMBL20329100 | 0.91 | HTR1A (0.89) | HTR2AHTR6HTR1AMPODRD2 | |
| SCHEMBL763446 | 0.90 | HTR2A (0.76) | HTR2AHTR6HTR1ABCHECYP2D6 | |
| SCHEMBL20244861 | 0.88 | HTR2A (0.78) | HTR2AHTR6HTR1AMPOBCHE | |
| SCHEMBL25295661 | 0.88 | HTR2A (1.00) | HTR2AHTR1AMPOHTR2CHTR2B | |
| SCHEMBL733629 | 0.88 | HTR2A (0.94) | HTR2AHTR1AMPOHTR2CHTR2B | |
| SCHEMBL29543272 | 0.88 | HTR2A (0.94) | HTR2AHTR1AMPOHTR2CHTR2B | |
| SCHEMBL11679648 | 0.87 | HTR2A (0.76) | HTR2AHTR6HTR1AMPOHTR2C | |
| SCHEMBL948662 | 0.86 | HTR6 (1.00) | HTR6HTR1AMPOBCHECYP2D6 | |
| SCHEMBL734226 | 0.86 | HTR2A (0.91) | HTR2AHTR1AMPOHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | ATAI THERAPEUTICS, INC. | 2023-05-09 | — | — | US | disclosed |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | ATAI THERAPEUTICS, INC. | 2023-05-09 | — | — | US | disclosed |
| US-20230041584-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022261383-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | ATAI Life Sciences AG (DE) | 2022-12-15 | — | — | WO | disclosed |
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2670733-B1 | N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-04-10 | — | — | EP | disclosed |
| US-RE47009-E1 | HDAC inhibitors and therapeutic methods using the same | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2018-08-28 | — | — | US | disclosed |
| US-9249087-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2670733-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2013-12-11 | — | — | EP | disclosed |
| CN-101516844-B | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH | 2013-12-11 | — | — | CN | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012106343-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012106343-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-08-09 | — | — | WO | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041584-A1 | NOVEL PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | NPY1R, NPY5R, HTR1A | HTR2A 13/4885HTR6 15/4885HTR1A 3/4885 |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HDAC1, HDAC9, HDAC8 | HTR2A 2483/4885HTR6 1743/4885HTR1A 2609/4885 |
| US-20230357146-A1 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | NPY1R, NPY5R, NPY2R | HTR2A 12/4885HTR6 13/4885HTR1A 5/4885 |
| US-11643391-B2 | Prodrugs and conjugates of dimethyltryptamine | NPY1R, NPY5R, NPY2R | HTR2A 12/4885HTR6 13/4885HTR1A 5/4885 |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | HTR2A 238/4885HTR6 254/4885HTR1A 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.